KRAS,BRAF oncogene mutations and tissue specific promoter hypermethylation of tumor suppressor SFRP2,DAPK1,MGMT,HIC1 and p16 genes in colorectal cancer patients

Adjei AA Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 2001; 93(14): 1062-1074.

Ahuja N , Mohan AL , Li Q , et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997; 57(16): 3370-3374.

Al-Mulla F , Going JJ , Sowden ET , Winter A , Pickford IR , Birnie GD . Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol 1998; 185(2): 130-138.

Andreyev HJ , Norman AR , Cunningham D , et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001; 85(5): 692-696.

Anjum R , Roux PP , Ballif BA , Gygi SP , Blenis J . The tumor suppressor DAP kinase is a target of RSK-mediated survival signaling. Curr Biol 2005; 15(19): 1762-1767.

Arrington AK , Heinrich EL , Lee W , et al. Prognostic and predictive roles of KRAS mutation in colorectal cancer. Int J Mol Sci 2012; 13(10): 12153-13168.

Arslan S , Akkurt I , Koksal B , Karadayi S , Ozdemir O . Predictive significance of KRAS point mutation in patients with non-small cell lung carcinoma relation to smoking and asbestos exposure in middle Anatolia population. Healthmed 2010; 4: 715-719.

Arslan S , Dogan T , Koksal B , et al. Tumoral tissue specific promoter hypermethylation of distinct tumor suppressor genes in a case with nonsmall cell lung carcinoma: A case report. Lung India 2008; 25(4): 148-151.

Berg M , Danielsen SA , Ahlquist T , et al. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS ONE 2010; 5(11): e13978.

Brink M , de Goeij AF , Weijenberg MP , et al. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003; 24(4): 703-710.

Chang SC , Lin JK , Yang SH , Wang HS , Li AF , Chi CW . Relationship between genetic alterations and prognosis in sporadic colorectal cancer. Int J Cancer 2006; 118(7): 1721-1727.

Dahabreh IJ , Terasawa T , Castaldi PJ , Trikalinos TA . Systematic review: Anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med 2011; 154(1): 37-49.

Deng G , Bell I , Crawley S , et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191-195.

de Vogel S , Weijenberg MP , Herman JG , et al. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: Indications for distinct pathways and sequence of events. Ann Oncol 2009; 20(7): 1216-1222.

Diehl JA , Zindy F , Sherr CJ . Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev 1997; 11(8): 957-972.

Di Nicolantonio F , Martini M , Molinari F , et al. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 2008; 26(35): 5705-5712.

Dong SM , Lee EJ , Jeon ES , Park CK , Kim KM . Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol 2004; 18(2): 170-178.

Esteller M , Toyota M , Sanchez-Cespedes M , et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60(9): 2368-2371.

Guan RJ , Fu Y , Holt PR , Pardee AB . Association of K-ras mutations with p16 methylation in human colon cancer. Gastroenterology 1999; 116(5): 1063-1071.

Hawkins NJ , Lee JH , Wong JJ , Kwok CT , Ward RL , Hitchins MP . MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa. Mod Pathol 2009; 22(12): 1588-1599.

Heinemann V , Stintzing S , Kirchner T , Boeck S , Jung A . Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. Cancer Treat Rev 2009; 35(3): 62-267.

Huang Z , Li L , Wang J . Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci 2007; 52(9): 2287-2291.

Imamura Y , Morikawa T , Liao X , et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 2012; 18(17): 4753-4763.

Issa JP . Aging, DNA methylation and cancer. Crit Rev Oncol Hematol 1999; 32(1): 31-43.

Kawakami K , Ruszkiewicz A , Bennett G , et al. DNA hypermethylation in the normal colonic mucosa of patients with colorectal cancer. Br J Cancer 2006; 94(4): 593-598.

Lee M , Han WS , Kim OK , et al. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer. Pathol Res Pract 2006; 202(6): 415-424.

Li HT , Lu YY , An YX , Wang X , Zhao QC . KRAS, BRAF and PIK3CA mutations in human colorectal cancer: Relationship with metastatic colorectal cancer. Oncol Rep 2011; 25(6): 1691-1697.

Liggett WH , Sidransky D . Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998; 16(3): 1197-1206.

Minoo P , Baker K , Goswami R , et al. Extensive DNA methylation in normal colorectal mucosa in hyperplastic polyposis. Gut 2006; 55(10): 1467-1474.

Moerkerk P , Arends JW , van Driel M , de Bruïne A , de Goeij A , ten Kate J . Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. Cancer Res 1994; 54(13): 3376-3378.

Morton RF , Hammond EH . ASCO Provisional Clinical Opinion: KRAS, Cetuximab, and Panitumumab-Clinical Implications in Colorectal Cancer. J Oncol Pract 2009; 5(2): 71-72.

Namba H , Nakashima M , Hayashi T , et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003; 88(9): 4393-4397.

Nash GM , Gimbel M , Shia J , et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol 2010; 17(2): 572-578.

Nicoll G , Crichton DN , McDowell HE , Kernohan N , Hup TR , Thompson AM . Expression of the Hypermethylated in Cancer gene (HIC-1) is associated with good outcome in human breast cancer. Br J Cancer 2001; 85(12): 1878-1882.

Nosho K , Irahara N , Shima K , et al. Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS ONE 2008; 3(11): e3698.

Ogino S , Meyerhardt JA , Irahara N , et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009; 15(23): 7322-7329.

Rajagopalan H , Bardelli A , Lengauer C , Kinzler KW , Vogelstein B , Velculescu VE . Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418(6901): 934.

Rattner A , Hsieh JC , Smallwood PM , et al. A family of secreted proteins contains homology to the cysteine-rich ligand-binding domain of frizzled receptors. PNAS 1997; 94(7): 2859-2863.

Richman SD , Seymour MT , Chambers P , et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27(35): 5931-5937.

Samowitz WS , Curtin K , Schaffer D , Robertson M , Leppert M , Slattery ML . Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Pre 2000; 9(11): 1193-1197.

Shannon BA , Iacopetta BJ . Methylation of the hMLH1, p16, and MDR1 genes in colorectal carcinoma: associations with clinicopathological features. Cancer Letters 2001; 167(1): 91-97.

Shen L , Kondo Y , Rosner GL , et al. MGMT promoter methylation and field defect in sporadic colorectal cancer. J Natl Cancer Inst 2005; 97(18): 1330-1338.

Shiloh R , Bialik S , Kimchi A . The DAPK family: A structure-function analysis. Apoptosis 2014; 19(2): 286-297.

Siegel R , DeSantis C , Jemal A . Colorectal cancer statistics, 2014. CA: A cancer journal for clinicians 2014; 64(2): 104-117.

Siena S , Sartore-Bianchi A , Di Nicolantonio F , Balfour J , Bardelli A . Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 2009; 101(19): 1308-1324.

Smith G , Bounds R , Wolf H , Steele RJC , Carey FA , Wolf CR . Activating K-Ras mutations outwith `hotspot' codons in sporadic colorectal tumours-implications for personalised cancer medicine. Br J Cancer 2010; 102(4): 693-703.

Sui C , Wang G , Chen Q , Ma J . Variation risks of SFRP2 hypermethylation between precancerous disease and colorectal cancer. Tumor Biology 2014; 35(10): 10457-10465.

Suzuki H , Watkins DN , Jair KW , et al. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004; 36(4): 417-422.

Sweeney C , Boucher KM , Samowitz WS , et al. Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes, Chromosomes and Cancer 2009; 48(1): 1-9.

Tanaka N , Huttenhower C , Nosho K , et al. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. Am J Pathol 2010; 177(6): 2731-2740.

Tol J , Punt CJ . Monoclonal antibodies in the treatment of metastatic colorectal cancer: A review. Clin Ther 2010; 32(3): 437-453.

Van Cutsem E , Köhne CH , Láng I , et al. Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status. J Clin Oncol 2011; 29(15): 2011-2019.

Wang DR , Tang D . Hypermethylated SFRP2 gene in fecal DNA is a high potential biomarker for colorectal cancer noninvasive screening. World J Gastroenterol 2008; 14(4): 524-531.

Wu CM , Tang R , Wang JY , Changchien CR , Hsieh LL . Frequency and spectrum of K-RAS codons 12 and 13 mutations in colorectal adenocarcinomas from Taiwan. ancer Genet Cytogenet 2005; 158(1): 55-60.

Yen LC , Uen YH , Wu DC , et al. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab. Ann Surg 2010; 251(2): 254-260.

Yokota T , Ura T , Shibata N , et al. BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 2011; 104(5): 856-862.